TYL vs URGN · P/E 89, rev $1.26B vs rev $109.8M
Tyler Technologies Inc (TYL) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Tyler Technologies Inc (TYL) is a software - application company listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported TYL revenue for 2026-06-30 was $1.26B. Net income was $174.7M. TYL currently screens at market cap $25.57B and trailing P/E 89.3.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. URGN currently screens at market cap $1.61B.
TYL currently screens at market cap $25.57B and trailing P/E 89.3. URGN currently screens at market cap $1.61B.
Not investment advice. Open the TYL and URGN stock pages for the full models.
Not investment advice.